The New Era of Drug Therapy for Obesity: The Evidence and the Expectations
Open accessThe DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index.
Abstract
There is an urgent need for effective pharmacological therapies to help tackle the growing obesity epidemic and the healthcare crisis it poses. The past 3 years have seen approval of a number of novel anti-obesity drugs. The majority of these influence hypothalamic appetite pathways via dopaminergic or serotoninergic signalling. Some are combination therapies, allowing lower doses to minimize the potential for off-target effects. An alternative approach is to mimic endogenous satiety signals using long-lasting forms of peripheral appetite-suppressing hormones. There is also considerable interest in targeting thermogenesis by brown adipose tissue to increase resting energy expenditure. Obesity pharmacotherapy has seen several false dawns, but improved understanding of the pathways regulating energy balance, and better-designed trials, give many greater confidence that recently approved agents will be both efficacious and safe. Nevertheless, a number of issues from preclinical and clinical development continue to attract debate, and additional large-scale trials are still required to address areas of uncertainty.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 1×
“A reduction in body weight of 5–10 % is enough for significant improvements in cardiovascular risk factor profiles [28–32], kidney disease [33] and osteoarthritis [34].”
BackgroundGlobal status report on noncommunicable diseases 2010.
Alwan, A. (2011) · Cited by 8,494
Genetics of Food Intake Self-Regulation in Childhood: Literature Review and Research Opportunities
Faith, M. S., Carnell, S., & Kral, T. V. E. (2013) · Human Heredity · doi:10.1159/000353879 · Cited by 7,601
Identification and Importance of Brown Adipose Tissue in Adult Humans
Cypess, A. M., Lehman, S., Williams, G., Tal, I., Rodman, D., Goldfine, A. B., Kuo, F. C., Palmer, E. L., Tseng, Y.-H., Doria, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810780 · Cited by 4,399
Predicting Obesity in Young Adulthood from Childhood and Parental Obesity
Whitaker, R. C., Wright, J. A., Pepe, M. S., Seidel, K. D., & Dietz, W. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709253371301 · Cited by 4,397
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.004 · Cited by 4,058
European Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432
Global burden of obesity in 2005 and projections to 2030
Kelly, T., Yang, W., Chen, C.-S., Reynolds, K., & He, J. (2008) · International Journal of Obesity · doi:10.1038/ijo.2008.102 · Cited by 3,319 · cited 1×
“Current projections anticipate that 20 % of adults will be obese by 2030 [4].”
BackgroundFunctional Brown Adipose Tissue in Healthy Adults
Virtanen, K. A., Lidell, M. E., Orava, J., Heglind, M., Westergren, R., Niemi, T., Taittonen, M., Laine, J., Savisto, N.-J., Enerbäck, S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808949 · Cited by 3,058 · cited 1×
“Well known as a source of non-shivering thermogenesis in human infants, it was assumed not to persist into adulthood, until review of positron emission tomography (PET) images from adult cancer patients revealed extensive glucose-avid areas in the neck and thorax, subsequently identified as brown fat [16, 17].”
BackgroundGut hormone PYY3-36 physiologically inhibits food intake
Batterham, R. L., Cowley, M. A., Small, C. J., Herzog, H., Cohen, M. A., Dakin, C. L., Wren, A. M., Brynes, A. E., Low, M. J., Ghatei, M. A., et al. (2002) · Nature · doi:10.1038/nature00887 · Cited by 2,351
Self-citation
Cited by
Anti-obesity therapy: from rainbow pills to polyagonists
Müller, T. D., Clemmensen, C., Finan, B., DiMarchi, R. D., & Tschöp, M. H. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014803 · Cited by 199
Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
Knerr, P. J., Mowery, S. A., Douros, J. D., Premdjee, B., Hjøllund, K. R., He, Y., Kruse Hansen, A. M., Olsen, A. K., Perez-Tilve, D., DiMarchi, R. D., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101533 · Cited by 152
Knerr, P. J., Mowery, S. A., Finan, B., Perez-Tilve, D., Tschöp, M. H., & DiMarchi, R. D. (2020) · Peptides · doi:10.1016/j.peptides.2019.170225 · Cited by 49
Provider attitudes and practice patterns of obesity management with pharmacotherapy
Granara, B., & Laurent, J. (2017) · Journal of the American Association of Nurse Practitioners · doi:10.1002/2327-6924.12481 · Cited by 36
“All agents produce their effects by reducing food intake or nutrient absorption and/or increasing resting or activity-related energy expenditure (Jones & Bloom, 2015).”
BackgroundEpidemiology of Obesity and Pharmacologic Treatment Options
Shettar, V., Patel, S., & Kidambi, S. (2017) · Nutrition in Clinical Practice · doi:10.1177/0884533617713189 · Cited by 26
“Along those lines, several peptide hormone combinations, including leptin, amylin mimetics, neuropeptide Y (NPY), oxyntomodulin, glucagon, and fibroblast growth factor 21 agonists, are being explored either alone or in combination therapy, particularly with GLP-1 agonists.(213,216,217) While monotherapy with recombina…”
Background
Metadata
- Authors
- Jones, B. J., & Bloom, S. R.
- Affiliations
- Hammersmith Hospital (GB)
- Corresponding author
- Bloom, Stephen R.
- Venue
- Drugs
- Published
- 2015-05-19
- Volume
- 75
- Issue
- 9
- Pages
- 935-945
- ISSN
- 0012-6667 (ISSN-L)
- 1179-1950
- PMC
- PMC4464860
- OpenAlex
- W2118611271
- Cited by
- 58
- References
- 106
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 4 · 2023: 1 · 2022: 4 · 2021: 3 · 2020: 8 · 2019: 8 · 2018: 4 · 2017: 9 · 2016: 12 · 2015: 2
- FWCI
- 6.44
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Drugs (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- National Institute for Health and Care Research (FP7-HEALTH-2009-241592, FP7-HEALTH-2009-241592 EuroCHIP, NF-SI-0513-10080, NF-SI-0507-10337, ACF-2010-21-012, NF-SI-0513-10029)
- Imperial College London
- Directorate for Biological Sciences
- Medical Research Council (FP7-HEALTH-2009-241592, MR/K02115X/1, MR/K023667/1, MR/L013088/1)
- Biotechnology and Biological Sciences Research Council (BB/L004259/1, FP7-HEALTH-2009-241592 EuroCHIP, FP7-HEALTH-2009-241592)
- NIHR Imperial Biomedical Research Centre
- FP7 Health (2009-241592 EuroCHIP)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- anti-obesity drugs, obesity pharmacotherapy, appetite regulation, dopamine signaling, combination therapy, satiety hormones, brown adipose tissue, thermogenesis, resting energy expenditure, energy balance, drug approval, drug safety
- MeSH terms
- Energy Metabolism, Forecasting, Humans, Obesity, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The New Era of Drug Therapy for Obesity: The Evidence and the Expectations. https://app.cochat.ai/papers/10.1007/s40265-015-0410-1
- The paper
- Jones, B. J., & Bloom, S. R. (2015). The New Era of Drug Therapy for Obesity: The Evidence and the Expectations. Drugs. https://doi.org/10.1007/s40265-015-0410-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.